Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Updated Rules OK’ed for FY2024 Reform, 5-10% Rate Set for New Premium to Counter Lag/Loss
January 18, 2024
- 9 APIs to Earn Increased Premiums in FY2024 Price Revision; Jakavi Gets Multiple Premiums
January 18, 2024
- MHLW Publishes Report on Drug Marketing System towards PMD Law Amendment
January 17, 2024
- MHLW Issues Notification to Clarify Orphan Designation Criteria
January 17, 2024
- FY2024 Reform Will Bolster Rewards for Innovation to Eradicate Drug Lag/Loss: LDP Policy Bigwig
January 16, 2024
- Legal Changes Needed to Push Use of Pseudonymized Data in Drug R&D: MHLW Working Group
January 16, 2024
- MHLW’s Planned Bill Would Exclude Certain Programs from “Specified Clinical Trials”
January 16, 2024
- MHLW Plans to Submit 4 Bills to This Year’s Ordinary Diet Session
January 16, 2024
- New LLP Coverage Rule Aimed to Transform Industry Rather Than Eke Out Savings: LDP Social Security Chief
January 15, 2024
- MHLW Issues Notification on Pediatric Development Plans
January 15, 2024
- Pharma Regulation Panel to Explore Potential Criteria for All-Case PMS Requirement
January 15, 2024
- Nobelpharma’s Hypozincemia Med, Jardiance’s CKD Use Up for PAFSC Review
January 15, 2024
- Japan Designates Noto Peninsula Quake as Severe Disaster
January 12, 2024
- MHLW Study Underway on Lab Monkey Shortage, Research Team Frets Dependence on Specific Sources
January 11, 2024
- MHLW Orders Label Revisions for Keytruda, Tecentriq, and More
January 11, 2024
- Handling of Big-Seller Candidates Is Top Priority as Japan Seeks Good Budget Balance: Minister
January 10, 2024
- Drugs Being Delivered to Quake-Hit Areas Day after Request: Minister
January 10, 2024
- Panels Urge OTC Switches “within 3 Years” for Drugs Sold Over the Counter in 2 or More Other Countries
January 5, 2024
- MHLW Unveils Draft Guidelines on Access to Intractable, Pediatric Disease Databases
January 5, 2024
- FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…